OncoMatch/Clinical Trials/NCT04638790

First Line Chemotherapy for Classical Hodgkin Lymphoma in Russia (HL-Russia-1)

Is NCT04638790 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments for hodgkin lymphoma, adult.

Phase 3RecruitingState Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of RussiaNCT04638790Data as of May 2026

Treatment: Doxorubicin · Bleomycin · Vinblastine · Dacarbazine · Etoposide · Doxorubicin · Cyclophosphamide · Vincristine · Dexamethasone · Dacarbazine — The HL-Russia-1 is a non-randomized, open-label, multicenter, phase III, 3-arm study. The primary objective is to assess efficacy, safety and progression-free survival (PFS) of different approaches (earle favorable, early unfavorable and advanced stages) to first line chemotherapy for classical Hodgkin Lymphoma (HL).

Check if I qualify

Extracted eligibility criteria

Cancer type

Hodgkin Lymphoma

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Prior therapy

No prior treatment (treatment-naive required)

Max 0 prior lines

Cannot have received: chemotherapy

Cannot have received: radiation therapy

Lab requirements

Blood counts

absolute neutrophil count >1,0 x109/L, platelets >75 x109/L

Kidney function

Creatinine within normal institutional limits or creatinine clearance >50 mL/min/1.73 m2

Liver function

Total bilirubin <2 mg/dl without a pattern consistent with Gilbert's syndrome

Cardiac function

Cardiac arrhythmia, conduction abnormalities, ischemic cardiopathy, left ventricular hypertrophy or LVEF ≤50% at echocardiography. Abnormal QTc interval prolonged (>450 msec in males; >470 msec in women)

Adequate organ and marrow function as defined below: absolute neutrophil count >1,0 x109/L, platelets >75 x109/L; Total bilirubin <2 mg/dl without a pattern consistent with Gilbert's syndrome; Creatinine within normal institutional limits or creatinine clearance >50 mL/min/1.73 m2; Cardiac arrhythmia, conduction abnormalities, ischemic cardiopathy, left ventricular hypertrophy or LVEF ≤50% at echocardiography. Abnormal QTc interval prolonged (>450 msec in males; >470 msec in women)

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify